Asset Details
Do you wish to reserve the book?
The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma
Do you wish to request the book?
The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma
2015
Overview
Background
There are no conclusive cost-effectiveness studies measuring the efficacy of salvage LT after liver resection (LR) and radiofrequency ablation (RFA) in patients with early hepatocellular carcinoma (HCC) and compensated cirrhosis. The aim of the present study is to compare liver transplantation (LT) versus locoregional therapy plus salvage LT (to treat tumor recurrence) in patients with early HCC and compensated cirrhosis.
Methods
Reference case: 55-year old male with HCC within Milan criteria and Child-Pugh A cirrhosis. The analysis was performed in two geographical cost settings: USA and Italy. Survival benefit measured in quality-adjusted life years (QALYs), costs (C) in US$, incremental cost-effectiveness, willingness to pay, and net health benefit (NHB).
Results
In the base-case analysis, NHB of LT vs. LR and RFA was −1.7 and −1.3 years for single tumor ≤3 cm, −1.2 and −0.7 for single nodules measuring 3.1–5 cm and −0.7 and −0.7 for multi-nodular tumor ≤3 cm in Italy. In USA, NHB of LT versus LR and RFA were −1.2 and −0.8 years for single tumor ≤3 cm, −0.9 and −0.5 for single nodules measuring 3.1–5 cm, and −0.5 and −0.4 for multi-nodular tumor ≤ 3 cm. On the Monte Carlo simulation, only young patients with multi-nodular HCC and short waiting list time had a positive NHB. Salvage LT proved to be an ineffective cost strategy after RFA or LR.
Conclusion
In patients with HCC within Milan criteria and Child-Pugh A cirrhosis, LR and RFA were more cost-effective than LT. Salvage LT was not cost-effective.
Publisher
Springer International Publishing,John Wiley & Sons, Inc
Subject
/ Carcinoma, Hepatocellular - complications
/ Carcinoma, Hepatocellular - pathology
/ Carcinoma, Hepatocellular - surgery
/ Catheter Ablation - economics
/ Humans
/ Italy
/ Liver Cirrhosis - complications
/ Liver Neoplasms - complications
/ Liver Transplantation - economics
/ Male
/ Medicine
/ Neoplasm Recurrence, Local - surgery
/ Surgery
/ Tace
